Amvuttra Market Report 2026

Amvuttra Market Overview

• The Amvuttra market growth in the historic period has been driven by advances in rna interference technology, unmet needs in ttr amyloidosis • Market expansion is supported by expansion of rna based pipelines, rising diagnosis rates of amyloidosis • Growth Driver: Rising Demand For Personalized Medicine Fueling The Growth Of The Market Due To The Need For Targeted Gene-Silencing Therapies • Market Trend: Advanced RNA-Silencing Therapies Boost Long-Term Treatment Efficacy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Amvuttra Market?

Amvuttra is a prescription small interfering RNA (siRNA) therapy designed to reduce the production of transthyretin (TTR) protein in the liver. By targeting and degrading the messenger RNA (mRNA) responsible for TTR synthesis, amvuttra helps prevent the formation of amyloid deposits. This treatment aims to alleviate symptoms such as pain, weakness, and impaired mobility, ultimately stabilizing or enhancing the patient's quality of life. The main type of indication for amvuttra is hereditary transthyretin-mediated amyloidosis (adult polyneuropathy, cardiomyopathy). Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare genetic disorder caused by a TTR gene mutation, leading to abnormal protein buildup that damages nerves, the heart, and other organs. It is distributed through several distribution channels, such as hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies, and is used by various end users, including adults and geriatrics.

What Is The Amvuttra Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of rna based pipelines, rising diagnosis rates of amyloidosis, improved genetic screening, increased orphan drug funding, long term efficacy data generation. Major trends in the forecast period include growth of sirna based therapies, expansion of disease modifying amyloidosis treatments, increased focus on genetic rare disorders, hospital centered advanced rna therapeutics, long term neurological outcome management.

Global Amvuttra Market Segmentation

1) By Indication: Adult Polyneuropathy, Cardiomyopathy 2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End-User: Adult, Geriatric

What Is The Driver Of The Amvuttra Market?

The rising demand for personalized medicine is expected to propel the growth of the amvuttra market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. Amvuttra enhances personalized medicine by delivering a gene-silencing therapy specifically designed to target and reduce transthyretin (TTR) protein production in patients with hereditary ATTR amyloidosis. It offers mutation-specific, precision-based treatment that improves clinical outcomes while supporting individualized patient care. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the amvuttra industry.

Key Players In The Global Amvuttra Market

Major companies operating in the amvuttra market are Alnylam Pharmaceuticals Inc.

Global Amvuttra Market Trends and Insights

Major companies operating in the amvuttra market are focusing on developing advanced RNA-silencing therapies to enhance long-term efficacy and patient access. RNA interference (RNAi) is a mechanism by which small interfering RNA molecules target and degrade messenger RNA to reduce production of disease-causing proteins, thereby offering sustained suppression of pathogenic proteins with infrequent dosing. For instance, in March 2025, U.S.-based Alnylam secured FDA approval for Amvuttra (vutrisiran) to treat transthyretin amyloid cardiomyopathy (ATTR-CM), and subsequently launched the therapy. Its key features include a competitive silencing mechanism, broad patient demand, a buy-and-bill reimbursement model, rapid uptake across both academic and community settings, a network of over 170 priority U.S. health systems, and demonstrated 48-month HELIOS-B trial data showing a 37 percent relative risk reduction in cardiovascular events.

What Are Latest Mergers And Acquisitions In The Amvuttra Market?

In April 2024, Medison Pharma, an Israel-based pharmaceutical company, expanded its partnership with Alnylam Pharmaceuticals Inc. to improve global access to Alnylam's innovative RNAi therapies for patients with rare diseases. This collaboration will utilize Medison's integrated commercialization platform across various regions, including Latin America (LATAM), the Asia-Pacific (APAC), and other international markets. Alnylam Pharmaceuticals, Inc. is a US-based pharmaceutical company that manufactures Amvuttra.

Regional Insights

North America was the largest region in the amvuttra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Amvuttra Market?

The amvuttra market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Amvuttra Market Report 2026?

The amvuttra market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the amvuttra industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.